NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Precision BioSciences, Inc. (DTIL) Stock Analysis

Precision BioSciences, Inc. (DTIL) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

DTIL

$7.47

+$0.10 (+1.36%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare DTIL with… →

DTIL Key Statistics

As of Sep 4, 2026
Trading
Open
$7.32
Previous Close
$7.37
Day's Range
7.32–7.58
52-Week Range
3.53–9.62
Volume
124.20K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.25
Valuation
Market Cap
$206.18M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
4.58
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.34
Financials (FY)
Revenue (FY)
$34.26M−50.12%
Net Income (FY)
−$45.72M−737.98%
Profit marginThe share of revenue left as profit after all costs and taxes.
−117.04%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
27.60M
1-Year Return
+48.51%
Dividend and dates
Earnings Date
November 2, 2026estimated
Avg Volume
419.00K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

DTIL Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+79.57%
2025+9.19%
2024−65.21%
2023−69.33%
2022−83.92%
2021−11.27%
2020−39.96%
2019 (partial year)−20.36%

As of September 4, 2026.

DTIL Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$34.26M−$45.72M−133.4%
2024$68.70M$7.17M10.4%
2023$48.73M−$61.32M−125.8%
2022$25.10M−$111.64M−444.8%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$34.26M—−$52.15M−$45.72M−133.4%
2024$68.70M—−$26.16M$7.17M10.4%
2023$48.73M—−$43.74M−$61.32M−125.8%
2022$25.10M—−$62.31M−$111.64M−444.8%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

DTIL Valuation vs Biotechnology Median

Median of 656 stocks
MetricDTILBiotechnology medianvs median
P/S ratio4.5815.260.3x the median
Profit margin−117.04%0.00%117.0 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Precision BioSciences, Inc. (DTIL) carries a market capitalisation of $206.18M. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 67 employees.

DTIL last closed at $7.47 on September 4, 2026. That is +$0.10 (+1.36%) against the previous close. The 52-week range on file runs from $3.53 to $9.62. The latest close sits 111.61% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $34.26M. Against the prior fiscal year total of $68.70M, that is a change of −50.12%. The same year closed with a net loss of $45.72M. The reported profit margin is −117.04%. That is 117 percentage points below the Biotechnology median of 0%. Trailing earnings per share are −1.34.

Across the 4 fiscal years on file, revenue moves from $25.10M in 2022 to $34.26M in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 4.58. On price-to-sales that is 0.3 times the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

The trailing one-year price return is +48.51%. Across 5 years the annualized return works out at −55.00%. Beta against the wider market is reported at 1.25. Annualized volatility over the trailing 7 years is 85.07%.

Growth & Income

The record shows no dividend for DTIL.

So far in 2026 the price is +79.57%. The strongest complete calendar year on file is 2025 at +9.19%; the weakest is 2022 at −83.92%. Of the 6 complete calendar years on file, 1 finished higher.

Peer Comparison

Precision BioSciences, Inc. (DTIL) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Precision BioSciences, Inc. DTIL $206.18M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Precision BioSciences, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Precision BioSciences, Inc.

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; and PBGENE-DMD (Excision) for the treatment of Duchenne muscular dystrophy. In addition, the company develops PBGENE-3243 for the treatment of m.3243 associated mitochondrial diseases; and iECURE-OTC (Insertion) for ornithine transcarbamylase deficiency. It has collaboration agreements with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azercabtagene zapreleucel for autoimmune diseases and other indications; and iECURE, Inc., an ARCUS-mediated targeted gene insertion. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Visit website →